Other documents
NordicAST BLBLI document:
β-LACTAM-β-LACTAMASE INHIBITOR COMBINATIONS AND NOVEL β-LACTAMS TARGETING GRAM-NEGATIVE BACTERIA
In this document we aim to show the expected inhibitory activity of β-lactamase inhibitors (BLIs) alone and the predicted efficacy of β-lactam-
β-lactamase inhibitor (BLBLI) combinations and cefiderocol against various β-lactamases affecting β-lactam susceptibility in
Gram-negative bacteria (Enterobacterales, Pseudomonas spp., and Acinetobacter baumannii group).
Methods descriptions
NordicAST recommends that susceptibility testing is performed according to EUCAST standardized methods.
Detailed methodology is available on the EUCAST website.
Method documents in quality control are available here.
FAQ
NordicAST receives many questions regarding susceptibility testing methods.
For questions regarding EUCAST's breakpoints and methods, refer to EUCAST's Frequently Asked Questions.
For further questions or Methodological problems, contact the responsible person in NordicAST (see contact information here).